Edition:
India

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

58.64USD
17 Nov 2017
Change (% chg)

$0.90 (+1.56%)
Prev Close
$57.74
Open
$57.84
Day's High
$59.09
Day's Low
$57.24
Volume
482,441
Avg. Vol
687,372
52-wk High
$61.57
52-wk Low
$17.52

Select another date:

Thu, Nov 2 2017

BRIEF-Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​

* Juno Therapeutics reports third quarter 2017 financial results

BRIEF-Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform

* Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform

BRIEF-Juno Therapeutics prices $250 million follow-on offering

* Juno Therapeutics- Announced pricing of its follow-on public offering of 6.1 million shares of its common stock at a price to public of $41.00 per share Source text for Eikon: Further company coverage:

BRIEF-Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing‍​

* Juno Therapeutics Inc - Files for offering of common stock; aggregate offering price of $225 million - SEC Filing‍​ Source text for Eikon: Further company coverage:

BRIEF-Juno Therapeutics qtrly ‍loss per share $0.96

* Juno Therapeutics reports second quarter 2017 financial results

UPDATE 1-Kite to launch mid-stage leukemia trial in fourth quarter 2017

CHICAGO, June 5 Kite Pharma Inc and Juno Therapeutics Inc on Monday presented new data for their experimental T-cell therapies, but investors were not overly impressed and shares of Juno fell nearly 11 percent.

Select another date: